Alzheimer's disease is a progressive, irreversible brain disorder with no known cause or cure. It is a lengthy multi-step process manifested by accrual of aberrant neuronal events that ultimately lead to accumulation of toxic aggregates and result in neuronal death. The protein Hsp90 has been recently identified as a key element that allows and sustains the accumulation of these aberrant events, suggesting that Hsp90-interfering drugs may represent a potential novel class of drugs for the treatment of Alzheimer’s disease. These drugs could promote the survival of neurons and therefore, may delay the onset of severe symptoms associated with the disease and further, improve the quality and length of these patients’ lives. Our laboratory has identified and developed such Hsp90 interfering agents, and in the current grant application we request funding to further develop these agents as possible novel therapeutics in Alzheimer’s disease and other neurodegenerative diseases.